COMPANY

Compass Therapeutics

HQ: Boston, MA source · compasstherapeutics.com ↗ · New England

3 open jobs · last seen Oct 23, 2026 · 8 sources

Our pipeline is focused on therapies that bridge the innate and adaptive immune system and includes therapies aimed at either activating or releasing immune suppression of T cells, NK cells, and macrophages. From company website Source · Oct 13, 2026

Keywords: Non Small Cell Lung Cancer Gastroesophageal Cancer Hepatocellular Carcinoma Endometrial Cancer Renal Cell Carcinoma Metastatic Colorectal Cancer Colon Cancer Rectal Cancer Biliary Tract Cancer Cholangiocarcinoma Gall Bladder Cancer Ampullary Cancer Triple Negative Breast Cancer Hodgkin Lymphoma Head and Neck Squamous Cell Carcinoma Malignant Melanoma Neuroendocrine Neoplasm Neuroendocrine Carcinomas Neuroendocrine Tumors Small Cell Lung Cancer Mesothelioma Melanoma Head and Neck Cancer CTX-009 CTX-471 CTX-10726 CTX-8371

Profile checked Oct 10, 2026

Since the raise (Aug 12, 2025): 3 of 3 open jobs were first seen after it.

3Open jobs $120.0MRaised (2 yrs)6Trials (company is sponsor)

Hiring

Title	Location (from posting)	Employer posted	First seen
Clinical Data Manager II	Boston, MA	Oct 21, 2026	Oct 22, 2026
Associate Director or Director of Pharmacovigilance Operations	Boston, MA	Aug 17, 2026	Oct 8, 2026
Medical Director	Boston, MA	Aug 18, 2025	Oct 8, 2026

See all 3 jobs

Timeline

Oct 8, 2026 Board tracked Radar started tracking this company’s job board (3 open jobs at last check). source ↗
2026-09 Trial start Phase 2: Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms source ↗
May 28, 2026 Trial start 1: A Phase 1 Study of the Safety and Tolerability of CTX-10726 source ↗
Aug 12, 2025 Raise Follow-on offering: $120M (total, as published), announced Aug 12, 2025. Source: SEC filing. source ↗
Mar 19, 2024 Trial start 1: A Phase 1 of CTX-8371 in Patients With Advanced Malignancies source ↗
Jan 9, 2023 Trial start Phase 2/Phase 3: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) source ↗
Dec 8, 2022 Trial start Phase 2: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer source ↗
May 17, 2019 Trial start Phase 1: Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies source ↗

Upcoming milestones

2026-12 (ESTIMATED) · 1 · A Phase 1 of CTX-8371 in Patients With Advanced Malignancies · NCT06150664
Aug 31, 2027 (ESTIMATED) · Phase 2/Phase 3 · A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) · NCT05506943
Apr 1, 2028 (ESTIMATED) · 1 · A Phase 1 Study of the Safety and Tolerability of CTX-10726 · NCT07419841
2028-09 (ESTIMATED) · Phase 2 · Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms · NCT07684170

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 3

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Clinical Data Manager II	Boston, MA	Oct 21, 2026	Oct 22, 2026	Not stated
Associate Director or Director of Pharmacovigilance Operations	Boston, MA	Aug 17, 2026	Oct 8, 2026	Senior
Medical Director	Boston, MA	Aug 18, 2025	Oct 8, 2026	Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $120.0M. Last 2 years.

Aug 12, 2025 Follow-on offering: $120M (total, as published), announced Aug 12, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT07419841	A Phase 1 Study of the Safety and Tolerability of CTX-10726	1	Recruiting	May 28, 2026	Apr 1, 2028 (estimated)
NCT05513742	A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer	Phase 2	Completed	Dec 8, 2022	May 15, 2025 (actual)
NCT05506943	A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)	Phase 2/Phase 3	Active, not recruiting	Jan 9, 2023	Aug 31, 2027 (estimated)
NCT06150664	A Phase 1 of CTX-8371 in Patients With Advanced Malignancies	1	Recruiting	Mar 19, 2024	2026-12 (estimated)
NCT07684170	Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms	Phase 2	Not yet recruiting	2026-09	2028-09 (estimated)
NCT03881488	Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies	Phase 1	Completed	May 17, 2019	May 21, 2025 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗

Connect

See your connections at Compass Therapeutics on LinkedIn

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18